The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who havebeen diagnosed with prostate-specific membrane antigen (PMSA)-positivecastration-resistant prostate cancer (mCRPC). Patients must have received at least 1prior androgen pathway inhibitor (ARPI) and cannot be treated by currently availabledrugs or clinical trials.In this program participants will be administered [Lu-177]-PNT2002 intravenously every 8weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. Duringtreatment, participants will be monitored with routine laboratory tests such as: - Hematology blood tests - Clinical Chemistry blood tests - Testosterone/Prostate Antigen levels blood test - Vital signs - Imaging - ECG

This study is for patients who have participated in a previous study and who continue toreceive benefit to have continued access to study drug and/or treatment.